Searchable abstracts of presentations at key conferences in endocrinology

ea0063p932 | Diabetes, Obesity and Metabolism 3 | ECE2019

Glucosuric drugs + immune checkpoint inhibitors: A recipe for diabetic ketoacidosis?

Kuzior Agnieszka , Fernandez-Trujillo-Comenge Paula Maria , Nivelo-Rivadeneira Manuel Esteban , Santana-Suarez Ana Delia , Acosta-Calero Carmen , Pedrianes-Matin Pablo Benito , Zajac Marta Agata , Martinez-Martin Francisco Javier

Introduction/Aim: Diabetic ketoacidosis is a rare complication in type 2 diabetic patients treated with SGLT2 inhibitors; usually there is a triggering factor (major trauma or surgery, sepsis) or misdiagnosis (type 1 diabetes or LADA). Nivolumab is an anti-CD279 monoclonal antibody used as a second-line immunotherapy in non-small cell lung carcinoma; its use has been associated with fulminant type 1 diabetes and other autoimmune endocrine diseases. We hereby present a case of ...